Evidence map›Paper›PMID 35412171›Full record

ArticleTargeted oncology2022

Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.

Toshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, Kan Yonemori, Tomoko Yanai, Douglas V Faller, Lwona Dobler, Neeraj Gupta, Farhad Sedarati, Kyu-Pyo Kim

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Targeted oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

Toshio ShimizuDepartment of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. tosshimi@ncc.go.jp.ORCID http://orcid.org/0000-0001-6632-0638
Yasutoshi KubokiNational Cancer Center Hospital East, Chiba, Japan.ORCID http://orcid.org/0000-0003-3675-953X
Chia-Chi LinNational Taiwan University Hospital, Taipei, Taiwan.ORCID http://orcid.org/0000-0002-2573-5789
Kan YonemoriDepartment of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0002-7624-7611
Tomoko YanaiTakeda Pharmaceutical Company Limited, Osaka, Japan.ORCID http://orcid.org/0000-0002-2753-5078
Douglas V FallerMillennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-2454-3478
Lwona DoblerMillennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5911-852X
Neeraj GuptaMillennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-5500-5218
Farhad SedaratiMillennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Kyu-Pyo KimAsan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID http://orcid.org/0000-0001-7848-5923
Takeda (United States) · USNational Cancer Center · USNational Cancer Center Hospital East · JPNational Taiwan University Hospital · TWTakeda (Japan) · JPTokyo National Hospital · JPUlsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35412171
PMCPMC9217764
OpenAlexW4223496630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.